Results 121 to 130 of about 52,753 (266)

Role of efavirenz plasma concentrations on long-term HIV suppression and immune restoration in HIV-infected children.

open access: yesPLoS ONE, 2019
BackgroundTo access the long term relationship between efavirenz plasma concentrations and evolution of HIV RNA loads and CD4 cell counts in children.MethodsRetrospective analysis of data from HIV-infected children on first line efavirenz-containing ...
Nontiya Homkham   +11 more
doaj   +1 more source

Perbandingan Penggunaan Efavirenz dan Nevirapine Terhadap Kolesterol LDL Pasien HIV/AIDS

open access: yesPharmaceutical Sciences and Research, 2019
Gangguan metabolik lipid merupakan kondisi yang sering ditemukan pada pasien HIV (Human Immunodeficiency Virus)/AIDS (Acquired Immuno Deficiency Syndrome) pada pasien yang menggunakan antiretroviral (ARV) lini pertama seperti efavirenz dan nevirapine ...
Anggriani Yusi   +5 more
doaj   +1 more source

Successful Desensitization ofEfavirenz in an 8 -year-Old HIV-Positive Child [PDF]

open access: yes, 2013
: Background & Aims: Allergic reaction is a common side effect of Efavirenz and drug replacement may not be an option to physicians. Here, a successful drug desensitization experiment on an 8-year-old female child over a period of 9 days is reported ...
Farokhnia M., M.D. ,Mohammadi M., B.Sc., Hosseininasab A., M.D.,
core  

Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices [PDF]

open access: yes, 2016
Aim: The non-nucleoside reverse transcriptase inhibitor efavirenz is one of the most prescribed antiretroviral therapeutics. Efavirenz-containing therapy has become associated with the occurrence of CNS side effects, including sleep disturbances ...
Curley, Paul   +3 more
core   +1 more source

How developing world concerns need to be part of drug development plans: A case study of four emerging antiretrovirals [PDF]

open access: yes, 2008
Clinical trials are usually designed to meet registration requirements in developed countries, and do not always address key concerns for use in developing countries.
Alexandra Calmy   +22 more
core   +3 more sources

Development and validation of a HPLC analytical assay method for efavirenz tablets: a medicine for HIV infections

open access: yesBrazilian Journal of Pharmaceutical Sciences, 2011
Efavirenz is a reverse transcriptase non analog nucleoside inhibitor used to treat HIV infections. A simple assay method by high performance liquid chromatography was developed and validated for efavirenz tablets. The physical chemical characteristics of
Osnir de Sá Viana   +9 more
doaj   +1 more source

Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.

open access: yesPLoS ONE, 2011
BackgroundImplication of pharmacogenetic variations and efavirenz pharmacokinetics in concomitant efavirenz based antiviral therapy and anti-tubercular drug induced liver injury (DILI) has not been yet studied.
Getnet Yimer   +10 more
doaj   +1 more source

Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia [PDF]

open access: yes, 2011
Objectives  To report immunovirological outcomes and resistance patterns in adults treated with triple combination antiretroviral therapy (cART) for 4 years in an HIV programme of Phnom Penh, Cambodia.
Balkan, Suna   +7 more
core   +2 more sources

Interaction and compatibility studies of efavirenz with pharmaceutical excipients

open access: yesJournal of Excipients and Food Chemicals, 2016
Although excipients have traditionally been thought of as being inert, experience has shown that there can be interactions between excipients and drugs. Thus, knowledge of potential physical and chemical interactions can be very useful. The compatibility
Cinira Fandaruff   +7 more
doaj  

Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz

open access: yesPediatric Health, Medicine and Therapeutics, 2014
Beatriz Larru,1 Jessica Eby,2,3 Elizabeth D Lowenthal2,4,51Department of Pediatrics, Division of Infectious Diseases, 2Department of Pediatrics, Division of General Pediatrics, Children's Hospital of Philadelphia, Philadelphia, 3Villanova University,
Larru B, Eby J, Lowenthal ED
doaj  

Home - About - Disclaimer - Privacy